Metabolomic comparison followed by cross-validation of enzyme-linked immunosorbent assay to reveal potential biomarkers of diabetic retinopathy in Chinese with type 2 diabetes

Zongyi Wang, Jiyang Tang, Enzhong Jin, Chi Ren, Siying Li, Linqi Zhang, Yusheng Zhong, Yu Cao, Jianmin Wang, Wei Zhou, Mingwei Zhao, Lvzhen Huang, Jinfeng QuFrontiers in Endocrinology 2022 · DOI

Abstract

This is the first study to compare the results of targeted and untargeted metabolomics via liquid chromatography-mass spectrometry to find the serum biomarkers which could reflect the metabolic variations among different stages of diabetic retinopathy (DR) in Chinese patients. The progression of DR at different critical stages was related to the serum levels of specific differential metabolites, showing a significant correlation between DR progression and increased indoleacetic acid (IAA) and decreased L-Citrulline (Cit), hexanoylcarnitine, chenodeoxycholic acid (CDCA), and eicosapentaenoic acid (EPA). Based on this study, it can be inferred that the accuracy of targeted metabolomics for metabolite expression in serum is higher than that of untargeted metabolomics. However, larger studies are needed to confirm these results.

Introduction

Diabetic retinopathy (DR) remains a leading cause of vision loss globally, particularly in China, which hosts the world's largest population of individuals with type 2 diabetes mellitus (T2DM). While traditional risk factors like hyperglycemia and diabetes duration are well-documented, they do not fully account for the varying rates of disease progression among patients.

Current diagnostic protocols often identify DR only after irreversible structural damage has occurred. Consequently, there is an urgent need for "liquid biopsy" biomarkers—measurable chemical signatures in the blood—that can signal the transition from simple T2DM to non-proliferative DR (NPDR) and eventually to the severe proliferative stage (PDR). This study aims to bridge the gap between high-throughput metabolomic discovery and clinical application through targeted validation.

Methodology

The researchers conducted a case-control study involving 110 Chinese participants, categorized into four distinct groups: healthy controls (n=27), T2DM without DR (n=27), NPDR (n=28), and PDR (n=28).

Overview of the metabolomics analysis workflow and study design.

The study utilized a dual-track analytical approach:

  1. Targeted Metabolomics: Using the Biocrates P500 platform and liquid chromatography-mass spectrometry (LC-MS/MS), 541 specific metabolites were quantified.
  2. Cross-Validation: Results were compared with a previous untargeted metabolomics study to identify overlapping, high-confidence biomarkers.
  3. Clinical Validation: Enzyme-Linked Immunosorbent Assays (ELISA) were employed to verify if the most promising metabolites (Cit, IAA, CDCA, and EPA) could be reliably detected using standard clinical laboratory tools.

Results and Key Insights

The study identified seven high-confidence biomarkers: L-Citrulline (Cit), indoleacetic acid (IAA), 1-methylhistidine (1-MH), phosphatidylcholines (PCs), hexanoylcarnitine, CDCA, and EPA.

Key Findings:

  • Diagnostic Accuracy: Indoleacetic acid (IAA) levels increased significantly as DR progressed, showing a high diagnostic ability to distinguish DR from T2DM (AUC = 0.867). Conversely, L-Citrulline (Cit) levels were significantly lower in NPDR patients compared to those with T2DM (AUC = 0.794).
  • Disease Severity Markers: CDCA and EPA levels dropped sharply during the transition from NPDR to PDR. EPA, in particular, demonstrated a strong correlation with disease severity (AUC = 0.810).
  • Methodological Superiority: A primary insight of the study is that targeted metabolomics provides significantly higher accuracy for serum metabolite expression than untargeted methods, making it more suitable for clinical diagnostic development.
  • Pathway Dysregulation: The progression of DR appears linked to specific dysfunctions in the arginine-to-citrulline pathway (vascular health) and the tryptophan-to-IAA pathway (neuroprotection).

Discussion and Limitations

While these findings provide a promising roadmap for earlier DR diagnosis, several limitations remain. The sample size of 110 subjects is relatively small, necessitating larger multi-center trials for broader validation. Furthermore, as a cross-sectional study, these results establish correlation rather than causation; it remains unclear if these metabolic shifts drive DR or are secondary effects of the disease. Finally, some markers like 1-methylhistidine lack commercially available ELISA kits, hindering immediate clinical implementation. Future longitudinal research is required to determine if these chemical fingerprints can predict DR onset before clinical symptoms appear on retinal scans.

Summary updated

Abstract

This is the first study to compare the results of targeted and untargeted metabolomics <i>via</i> liquid chromatography-mass spectrometry to find the serum biomarkers which could reflect the metabolic variations among different stages of DR in Chinese. The progression of DR in Chinese at different critical stages was related to the serum levels of specific differential metabolites, of which there is a significant correlation between DR progression and increased IAA and decreased Cit, hexanoylcarnitine, CDCA, and EPA. However, larger studies are needed to confirm our results. Based on this study, it could be inferred that the accuracy of targeted metabolomics for metabolite expression in serum is to some extent higher than that of untargeted metabolomics.
BibTeX
@inproceedings{wang2022metabolomic,
  author = {Zongyi Wang and Jiyang Tang and Enzhong Jin and Chi Ren and Siying Li and Linqi Zhang and Yusheng Zhong and Yu Cao and Jianmin Wang and Wei Zhou and Mingwei Zhao and Lvzhen Huang and Jinfeng Qu},
  title = {{Metabolomic comparison followed by cross-validation of enzyme-linked immunosorbent assay to reveal potential biomarkers of diabetic retinopathy in Chinese with type 2 diabetes}},
  booktitle = {Frontiers in Endocrinology},
  year = {2022},
  doi = {10.3389/fendo.2022.986303},
}
Figure